{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:23:10Z","timestamp":1787304190974,"version":"build-2736575974"},"reference-count":262,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer is a highly heterogeneous malignancy that remains one of the leading causes of cancer-related mortality among women worldwide. Despite significant advances in breast cancer research and therapy, disease heterogeneity, treatment resistance, and metastatic progression remain major obstacles to effective disease management. Among the molecular regulators involved in breast cancer, microRNAs (miRNAs) have been recognized as critical post-transcriptional regulators of gene expression, functioning as either oncogenes or tumor suppressors. By modulating the expression of target RNAs, miRNAs control key biological processes involved in tumor initiation and progression, including cell proliferation, apoptosis, angiogenesis, epithelial\u2013mesenchymal transition (EMT), invasion, and metastasis. To investigate miRNA function and explore their therapeutic potential, a wide range of approaches have been developed to modulate miRNA expression. These include gain-of-function strategies, like miRNA mimics, miRNA expression vectors, and CRISPR activation (CRISPRa), as well as loss-of-function approaches, including anti-miRNA oligonucleotides (AMOs), miRNA sponges, CRISPR-Cas9-mediated gene knockout, and CRISPR interference (CRISPRi). This review provides a comprehensive overview of the biological roles of miRNAs in breast cancer and discusses current technologies for miRNA modulation, their molecular mechanisms, experimental and therapeutic applications, and associated limitations. In addition, it summarizes recent advances in miRNA delivery systems, including viral vectors, organic nanoparticles, and inorganic nanocarriers, highlighting their potential to improve delivery efficiency, target specificity, and facilitate clinical translation. Finally, the review discusses future perspectives, emphasizing the transition from single-target interventions toward network-level regulation and the integration of miRNA-based strategies into precision oncology to support the development of more effective breast cancer therapies.<\/jats:p>","DOI":"10.3390\/cancers18162708","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:14:01Z","timestamp":1787300041000},"page":"2708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-4137","authenticated-orcid":false,"given":"Marios A.","family":"Diamantopoulos","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-3003","authenticated-orcid":false,"given":"Michaela A.","family":"Boti","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Kanellopoulos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-4949","authenticated-orcid":false,"given":"Andreas","family":"Scorilas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1074\/mcp.RA119.001576","article-title":"Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cell. Proteom."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100210","DOI":"10.1016\/j.medidd.2025.100210","article-title":"Understanding drug resistance in breast cancer: Mechanisms and emerging therapeutic strategies","volume":"26","author":"Gautam","year":"2025","journal-title":"Med. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19101","DOI":"10.1038\/s41598-023-44767-3","article-title":"Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients","volume":"13","author":"Saxena","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tjog.2013.10.002","article-title":"MicroRNAs regulate several functions of normal tissues and malignancies","volume":"52","author":"Wen","year":"2013","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101434","DOI":"10.1016\/j.imu.2023.101434","article-title":"Identification of dysregulated miRNAs and their roles in breast cancer; An in silico meta-analysis study","volume":"44","author":"Foruzandeh","year":"2024","journal-title":"Inform. Med. Unlocked"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Baylie, T., Kasaw, M., Getinet, M., Getie, G., Jemal, M., Nigatu, A., Ahmed, H., and Bogale, M. (2024). The role of miRNAs as biomarkers in breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1374821"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105188","DOI":"10.1016\/j.critrevonc.2026.105188","article-title":"Therapeutic potential of MicroRNAs in targeting breast cancer stem cells: A systematic review","volume":"221","author":"Ting","year":"2026","journal-title":"Crit. Rev. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13346-021-00999-2","article-title":"MicroRNAs as therapeutic targets in breast cancer metastasis","volume":"12","author":"Pouya","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/10428194.2018.1461861","article-title":"MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia","volume":"60","author":"Papageorgiou","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1515\/cclm-2016-0756","article-title":"Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients","volume":"55","author":"Diamantopoulos","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","article-title":"Targeted therapies in breast cancer: New challenges to fight against resistance","volume":"8","author":"Masoud","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer","volume":"234","author":"Mollaei","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Boti, M.A., Diamantopoulos, M.A., and Scorilas, A. (2025). RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics. Genes, 16.","DOI":"10.3390\/genes16101168"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Boti, M.A., Athanasopoulou, K., Adamopoulos, P.G., Sideris, D.C., and Scorilas, A. (2023). Recent Advances in Genome-Engineering Strategies. Genes, 14.","DOI":"10.3390\/genes14010129"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-030-20301-6_6","article-title":"Breast Cancer Heterogeneity in Primary and Metastatic Disease","volume":"1152","author":"Kalinowski","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2021.07.010","article-title":"Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies","volume":"82","author":"Zhao","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_19","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_20","unstructured":"Organisation, W.H. (2026, August 13). Breast Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: Presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3348\/kjr.2018.0231","article-title":"Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage","volume":"20","author":"Koh","year":"2019","journal-title":"Korean J. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kudela, E., Samec, M., Koklesova, L., Liskova, A., Kubatka, P., Kozubik, E., Rokos, T., Pribulova, T., Gabonova, E., and Smolar, M. (2020). miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207691"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: Pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Arun, R.P., Cahill, H.F., and Marcato, P. (2022). Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030651"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13414","DOI":"10.3390\/ijms131013414","article-title":"The role of microRNAs in breast cancer migration, invasion and metastasis","volume":"13","author":"Tang","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ghafouri-Fard, S., Khanbabapour Sasi, A., Abak, A., Shoorei, H., Khoshkar, A., and Taheri, M. (2021). Contribution of miRNAs in the Pathogenesis of Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.768949"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ijc.30142","article-title":"Subtype-specific micro-RNA expression signatures in breast cancer progression","volume":"139","author":"Haakensen","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35188","DOI":"10.18632\/oncotarget.9072","article-title":"mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.46142","article-title":"A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse","volume":"10","author":"Hong","year":"2020","journal-title":"Theranostics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/oncsis.2016.4","article-title":"Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine","volume":"5","author":"Peng","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"S\u00f8kilde, R., Persson, H., Ehinger, A., Pirona, A.C., Fern\u00f6, M., Hegardt, C., Larsson, C., Loman, N., Malmberg, M., and Ryd\u00e9n, L. (2019). Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genom., 20.","DOI":"10.1186\/s12864-019-5887-7"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Amorim, M., Lobo, J., Fontes-Sousa, M., Estev\u00e3o-Pereira, H., Salta, S., Lopes, P., Coimbra, N., Antunes, L., Palma de Sousa, S., and Henrique, R. (2019). Predictive and prognostic value of selected MicroRNAs in luminal breast cancer. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00815"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"McDermott, A.M., Miller, N., Wall, D., Martyn, L.M., Ball, G., Sweeney, K.J., and Kerin, M.J. (2014). Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087032"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Newie, I., S\u00f8kilde, R., Persson, H., Grabau, D., Rego, N., Kvist, A., von Stedingk, K., Axelson, H., Borg, \u00c5., and Vallon-Christersson, J. (2014). The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097200"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3892\/ol.2016.5482","article-title":"Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients","volume":"13","author":"Luo","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/0008-5472.CAN-10-1869","article-title":"Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2\/Her2 gene","volume":"71","author":"Persson","year":"2011","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.18632\/oncoscience.275","article-title":"Identification of new miRNA biomarkers associated with HER2-positive breast cancers","volume":"2","author":"Tashkandi","year":"2015","journal-title":"Oncoscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E2594","DOI":"10.1073\/pnas.1717820115","article-title":"Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy","volume":"115","author":"Floros","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12967-019-2086-x","article-title":"Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study","volume":"17","author":"Moi","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3892\/ijo.2015.2821","article-title":"Identification of dysregulated microRNAs in triple-negative breast cancer (Review)","volume":"46","author":"Yang","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C., and Foti, M. (2019). Deciphering miRNAs\u2019 Action through miRNA Editing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246249"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s10038-021-00938-6","article-title":"Cancer-associated miRNAs and their therapeutic potential","volume":"66","author":"Inoue","year":"2021","journal-title":"J. Hum. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.clbc.2019.08.010","article-title":"MicroRNA-4472 Promotes Tumor Proliferation and Aggressiveness in Breast Cancer by Targeting RGMA and Inducing EMT","volume":"20","author":"Li","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1080\/21655979.2021.1924543","article-title":"MicroRNA miR-92a-3p regulates breast cancer cell proliferation and metastasis via regulating B-cell translocation gene 2 (BTG2)","volume":"12","author":"Huang","year":"2021","journal-title":"Bioengineered"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e70542","DOI":"10.1002\/jbt.70542","article-title":"Exosomal miR-155-5p Modulates Breast Cancer Proliferation and Metastasis Via NF-\u03baB Activation","volume":"39","author":"Xu","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21873\/cgp.20147","article-title":"MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation","volume":"16","author":"Assiri","year":"2019","journal-title":"Cancer Genom. Proteom."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18632\/aging.204474","article-title":"miRNA-874-3p inhibits the migration, invasion and proliferation of breast cancer cells by targeting VDAC1","volume":"15","author":"Yang","year":"2023","journal-title":"Aging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/1759-7714.14437","article-title":"MiR-379-5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4A","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s11010-024-05136-4","article-title":"MicroRNA-205-5p inhibits the growth and migration of breast cancer through targeting Wnt\/\u03b2-catenin co-receptor LRP6 and interacting with lncRNAs","volume":"480","author":"Mohamed","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1111\/jcmm.14515","article-title":"miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2\/Wnt signalling pathway","volume":"23","author":"Chi","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_59","first-page":"e1974","article-title":"miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting ERBB2","volume":"7","author":"Li","year":"2024","journal-title":"Cancer Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, Z., Hu, S., Li, X., Liu, Z., Han, D., Wang, Y., Wei, L., Zhang, G., and Wang, X. (2021). MiR-16-5p suppresses breast cancer proliferation by targeting ANLN. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08914-1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.32604\/or.2024.057472","article-title":"Hsa-miR-214-3p inhibits breast cancer cell growth and improves the tumor immune microenvironment by downregulating B7H3","volume":"33","author":"Lu","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-021-00288-3","article-title":"MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer","volume":"26","author":"Ma","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Arabkari, V., Barua, D., Hossain, M.M., Webber, M., Smith, T., Gupta, A., and Gupta, S. (2023). miRNA-378 Is Downregulated by XBP1 and Inhibits Growth and Migration of Luminal Breast Cancer Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010186"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Morana, O., Wood, W., and Gregory, C.D. (2022). The Apoptosis Paradox in Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031328"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hassan, A., and Aubel, C. (2025). The PI3K\/Akt\/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17132232"},{"key":"ref_66","first-page":"5203839","article-title":"miR-641 Inhibited Cell Proliferation and Induced Apoptosis by Targeting NUCKS1\/PI3K\/AKT Signaling Pathway in Breast Cancer","volume":"2022","author":"Li","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s10495-023-01870-0","article-title":"microRNA-944 inhibits breast cancer cell proliferation and promotes cell apoptosis by reducing SPP1 through inactivating the PI3K\/Akt pathway","volume":"28","author":"Zhang","year":"2023","journal-title":"Apoptosis An. Int. J. Program. Cell Death"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/iub.2688","article-title":"MiR-548k suppresses apoptosis in breast cancer cells by affecting PTEN\/PI3K\/AKT signaling pathway","volume":"75","author":"Moayedi","year":"2023","journal-title":"IUBMB Life"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"155572","DOI":"10.1016\/j.prp.2024.155572","article-title":"MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities","volume":"262","author":"Syed","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.7150\/ijbs.48933","article-title":"MicroRNA-216b targets HK2 to potentiate autophagy and apoptosis of breast cancer cells via the mTOR signaling pathway","volume":"17","author":"Liu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10238-012-0186-5","article-title":"MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1","volume":"13","author":"Li","year":"2013","journal-title":"Clin. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgq209","article-title":"Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer","volume":"32","author":"Zhang","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21496","DOI":"10.1074\/jbc.M109.083337","article-title":"MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression","volume":"285","author":"Zhou","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_74","first-page":"1621","article-title":"PUMA is a novel target of miR-221\/222 in human epithelial cancers","volume":"37","author":"Zhang","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/S12094-009-0329-7","article-title":"Tumoral angiogenesis and breast cancer","volume":"11","year":"2009","journal-title":"Clin. Transl. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7150\/ijbs.37906","article-title":"TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer","volume":"16","author":"Zhong","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"153764","DOI":"10.1016\/j.prp.2022.153764","article-title":"Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics","volume":"230","author":"Hussen","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cabello, P., Torres-Ruiz, S., Adam-Artigues, A., For\u00e9s-Martos, J., Mart\u00ednez, M.T., Hernando, C., Zazo, S., Madoz-G\u00farpide, J., Rovira, A., and Burgu\u00e9s, O. (2023). miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15072138"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hunter, S., Nault, B., Ugwuagbo, K.C., Maiti, S., and Majumder, M. (2019). Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer. Cancers, 11.","DOI":"10.3390\/cancers11070938"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"471","DOI":"10.18632\/oncotarget.2509","article-title":"MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis","volume":"6","author":"Danza","year":"2015","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/biof.1702","article-title":"The HIF-1\/SNHG1\/miR-199a-3p\/TFAM axis explains tumor angiogenesis and metastasis under hypoxic conditions in breast cancer","volume":"47","author":"Zuo","year":"2021","journal-title":"BioFactors"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Resendiz-Hern\u00e1ndez, M., Garc\u00eda-Hern\u00e1ndez, A.P., Silva-C\u00e1zares, M.B., Coronado-Uribe, R., Hern\u00e1ndez-de la Cruz, O.N., Arriaga-Pizano, L.A., Prieto-Ch\u00e1vez, J.L., Salinas-Vera, Y.M., Ibarra-Sierra, E., and Ortiz-Mart\u00ednez, C. (2024). MicroRNA-204 Regulates Angiogenesis and Vasculogenic Mimicry in CD44+\/CD24- Breast Cancer Stem-like Cells. Non-Coding RNA, 10.","DOI":"10.3390\/ncrna10010014"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/cgt.2017.30","article-title":"MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer","volume":"24","author":"Lu","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.31557\/APJCP.2019.20.1.193","article-title":"MiR-126 Modulates Angiogenesis in Breast Cancer by Targeting VEGF-A -mRNA","volume":"20","author":"Alhasan","year":"2019","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biopha.2016.03.007","article-title":"miR-195 inhibits tumor growth and angiogenesis through modulating IRS1 in breast cancer","volume":"80","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10020-020-00239-2","article-title":"ZLM-7 inhibits the occurrence and angiogenesis of breast cancer through miR-212-3p\/Sp1\/VEGFA signal axis","volume":"26","author":"Li","year":"2020","journal-title":"Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"115927","DOI":"10.1016\/j.taap.2022.115927","article-title":"Breast cancer cells-derived Von Willebrand Factor promotes VEGF-A-related angiogenesis through PI3K\/Akt-miR-205-5p signaling pathway","volume":"440","author":"Tao","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","article-title":"Mutational drivers of cancer cell migration and invasion","volume":"124","author":"Novikov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/1566523222666220901112314","article-title":"miRNA-1260b Promotes Breast Cancer Cell Migration and Invasion by Downregulating CCDC134","volume":"23","author":"Huang","year":"2023","journal-title":"Curr. Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3727\/096504021X16274672547967","article-title":"miR-142-5p Inhibits Cell Invasion and Migration by Targeting DNMT1 in Breast Cancer","volume":"28","author":"Li","year":"2022","journal-title":"Oncol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/nm.3336","article-title":"The epigenetics of epithelial-mesenchymal plasticity in cancer","volume":"19","author":"Tam","year":"2013","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"151777","DOI":"10.1016\/j.acthis.2021.151777","article-title":"MiR-337-3p suppresses migration and invasion of breast cancer cells by downregulating ESRP1","volume":"123","author":"Pan","year":"2021","journal-title":"Acta Histochem."},{"key":"ref_94","first-page":"137","article-title":"MIR-518a-5p Targets ZEB2 to Suppress the Migration and Invasion of Breast-cancer Cells","volume":"29","author":"Wang","year":"2023","journal-title":"Altern. Ther. Health Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"14783","DOI":"10.1002\/jcp.28277","article-title":"The crucial role of ZEB2: From development to epithelial-to-mesenchymal transition and cancer complexity","volume":"234","author":"Fardi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12282-019-00989-w","article-title":"MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1","volume":"26","author":"Zhao","year":"2019","journal-title":"Breast Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2018.08.172","article-title":"miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522","volume":"504","author":"Li","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.2147\/OTT.S142610","article-title":"KIA1522 overexpression promotes tumorigenicity and metastasis of esophageal cancer cells through potentiating the ERK activity","volume":"10","author":"Xie","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.clinsp.2022.100115","article-title":"MiR-135a-5p suppresses breast cancer cell proliferation, migration, and invasion by regulating BAG3","volume":"77","author":"Zhang","year":"2022","journal-title":"Clinics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3892\/or.2015.4502","article-title":"MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1","volume":"35","author":"Jiang","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_101","first-page":"615","article-title":"MicroRNA-548m Suppresses Cell Migration and Invasion by Targeting Aryl Hydrocarbon Receptor in Breast Cancer Cells","volume":"28","author":"Chung","year":"2021","journal-title":"Oncol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1002\/jcb.26767","article-title":"microRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway","volume":"119","author":"Han","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_103","first-page":"400","article-title":"miR-532-5p promotes breast cancer proliferation and migration by targeting RERG","volume":"19","author":"Huang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s11658-022-00393-x","article-title":"Downregulation of exosomal miR-7-5p promotes breast cancer migration and invasion by targeting RYK and participating in the atypical WNT signalling pathway","volume":"27","author":"Liang","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","article-title":"Pre-metastatic niche: Formation, characteristics and therapeutic implication","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-020-00700-z","article-title":"Cancer-derived exosomal miR-7641 promotes breast cancer progression and metastasis","volume":"19","author":"Shen","year":"2021","journal-title":"Cell Commun. Signal. CCS"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/1759-7714.14284","article-title":"miR-223-3p targets FBXW7 to promote epithelial-mesenchymal transition and metastasis in breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.tice.2021.101581","article-title":"miR-934 promotes breast cancer metastasis by regulation of PTEN and epithelial\u2013mesenchymal transition","volume":"71","author":"Lu","year":"2021","journal-title":"Tissue Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2500104","DOI":"10.1080\/15384047.2025.2500104","article-title":"Exosomal miR-122-5p for regulation of secretory functions of fibroblasts and promotion of breast cancer metastasis by targeting MKP-2: An experimental study","volume":"26","author":"Lv","year":"2025","journal-title":"Cancer Biol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41417-021-00348-y","article-title":"Fatty acid \u03b2-oxidation promotes breast cancer stemness and metastasis via the miRNA-328-3p-CPT1A pathway","volume":"29","author":"Zeng","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00432-023-05601-5","article-title":"In vivo validation of the functional role of MicroRNA-4638-3p in breast cancer bone metastasis","volume":"150","author":"Akshaya","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3892\/or.2023.8661","article-title":"MicroRNA-606 inhibits the growth and metastasis of triple-negative breast cancer by targeting Stanniocalcin 1","volume":"51","author":"Choi","year":"2024","journal-title":"Oncol. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"216995","DOI":"10.1016\/j.canlet.2024.216995","article-title":"Deciphering the TCF19\/miR-199a-5p\/SP1\/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition","volume":"597","author":"Li","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1078-0432.CCR-16-0943","article-title":"miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1\/IL11 Pathway","volume":"23","author":"Samaeekia","year":"2017","journal-title":"Clin. Cancer Res. An. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncrna.2016.10.003","article-title":"Role of let-7 family microRNA in breast cancer","volume":"1","author":"Thammaiah","year":"2016","journal-title":"Non-Coding RNA Res."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Manore, S.G., Doheny, D.L., Wong, G.L., and Lo, H.W. (2022). IL-6\/JAK\/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.866014"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"113191","DOI":"10.1016\/j.intimp.2024.113191","article-title":"MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK\/c-Jun and p38 MAPK signaling pathway activation","volume":"142","author":"Gu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yexcr.2017.05.007","article-title":"MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3","volume":"357","author":"Xiang","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3892\/or.2017.5393","article-title":"miR520c blocks EMT progression of human breast cancer cells by repressing STAT3","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-015-0526-y","article-title":"Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management","volume":"17","author":"Wildiers","year":"2015","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/jcp.26514","article-title":"Treating cancer with microRNA replacement therapy: A literature review","volume":"233","author":"Hosseinahli","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-60761-863-8_15","article-title":"The guideline of the design and validation of MiRNA mimics","volume":"Volume 676","author":"Clifton","year":"2011","journal-title":"MicroRNA and Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbrc.2019.02.075","article-title":"A novel method for stabilizing microRNA mimics","volume":"511","author":"Nogimori","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3892\/mmr.2021.11839","article-title":"miR-653-5p suppresses the growth and migration of breast cancer cells by targeting MAPK6","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: Rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1007\/s11095-011-0548-9","article-title":"MicroRNA replacement therapy for cancer","volume":"28","author":"Henry","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.biopha.2017.04.119","article-title":"Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors","volume":"91","author":"Tavanafar","year":"2017","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2021.09.033","article-title":"SLC7A11\/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells","volume":"522","author":"Yadav","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.21037\/tcr.2019.01.21","article-title":"miR-30b suppresses the progression of breast cancer through inhibition of the PI3K\/Akt signaling pathway by targeting Derlin-1","volume":"8","author":"Zhou","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.genrep.2025.102211","article-title":"MicroRNA-34a enhances immune response and suppresses PI3K\/AKT signaling through targeting PD-L1 in triple-negative breast cancer","volume":"40","author":"Tavakolpour","year":"2025","journal-title":"Gene Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymeth.2012.07.019","article-title":"Generation of MiRNA Sponge Constructs","volume":"58","author":"Kluiver","year":"2012","journal-title":"Methods"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.addr.2014.05.010","article-title":"Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells","volume":"81","author":"Tay","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-981-13-1426-1_6","article-title":"Circular RNAs Act as miRNA Sponges","volume":"1087","author":"Panda","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jbiotec.2016.09.011","article-title":"Circular RNAs are miRNA sponges and can be used as a new class of biomarker","volume":"238","author":"Kulcheski","year":"2016","journal-title":"J. Biotechnol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3892\/or.2016.4596","article-title":"MiRNA-10b sponge: An anti-breast cancer study in vitro","volume":"35","author":"Liang","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.actbio.2015.07.020","article-title":"miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy","volume":"25","author":"Gao","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Rama, A.R., Lara, P., Mesas, C., Qui\u00f1onero, F., V\u00e9lez, C., Melguizo, C., and Prados, J. (2022). Circular Sponge against miR-21 Enhances the Antitumor Activity of Doxorubicin against Breast Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314803"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1016\/j.ymthe.2025.07.039","article-title":"The chimeric aptamer axl-miR-214sponge inhibits breast cancer and melanoma dissemination","volume":"33","author":"Quirico","year":"2025","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Bravo-Estupi\u00f1an, D.M., Gei\u00df, C., Arias-Arias, J.L., Monta\u00f1o-Samaniego, M., Chinchilla-Monge, R., Mar\u00edn-M\u00fcller, C., Quir\u00f3s-Barrantes, S., R\u00e9gnier-Vigouroux, A., Ib\u00e1\u00f1ez-Hern\u00e1ndez, M., and Mora-Rodr\u00edguez, R.A. (2025). A Synthetic Sponge System Against miRNAs of the miR-17\/92 Cluster Targets Transcriptional MYC Dosage Compensation in Aneuploid Cancer. Cells, 14.","DOI":"10.3390\/cells14171384"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"20370","DOI":"10.18632\/oncotarget.4827","article-title":"Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge","volume":"6","author":"Jung","year":"2015","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s11095-010-0156-0","article-title":"A direct comparison of anti-microRNA oligonucleotide potency","volume":"27","author":"Lennox","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.gt.3302654","article-title":"Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease?","volume":"13","author":"Weiler","year":"2006","journal-title":"Gene Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Pagoni, M., Cava, C., Sideris, D.C., Avgeris, M., Zoumpourlis, V., Michalopoulos, I., and Drakoulis, N. (2023). miRNA-Based Technologies in Cancer Therapy. J. Pers. Med., 13.","DOI":"10.3390\/jpm13111586"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"11650","DOI":"10.1038\/srep11650","article-title":"The role of miR-100 in regulating apoptosis of breast cancer cells","volume":"5","author":"Gong","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"110771","DOI":"10.1016\/j.compbiomed.2025.110771","article-title":"Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors","volume":"196","author":"Kamali","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12015-019-09944-w","article-title":"Delivery of LNA-antimiR-142-3p by Mesenchymal Stem Cells-Derived Exosomes to Breast Cancer Stem Cells Reduces Tumorigenicity","volume":"16","author":"Naseri","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12032-025-02935-7","article-title":"Targeting miR-32-5p suppresses c-MYC-driven proliferation and induces apoptosis in MCF-7 breast cancer cells","volume":"42","author":"Khoder","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1038\/s41598-021-90972-3","article-title":"Stable duplex-linked antisense targeting miR-148a inhibits breast cancer cell proliferation","volume":"11","author":"Okumura","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-genet-110410-132430","article-title":"CRISPR-Cas systems in bacteria and archaea: Versatile small RNAs for adaptive defense and regulation","volume":"45","author":"Bhaya","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"ref_154","first-page":"32","article-title":"Targeting miRNA by CRISPR\/Cas in cancer: Advantages and challenges","volume":"10","author":"Hussen","year":"2023","journal-title":"Mil. Med. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1800132","DOI":"10.1002\/adbi.201800132","article-title":"CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy","volume":"2","author":"Mintz","year":"2018","journal-title":"Adv. Biosyst."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12935-022-02654-3","article-title":"CRISPR\/Cas9 system in breast cancer therapy: Advancement, limitations and future scope","volume":"22","author":"Karn","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/bit.28603","article-title":"CRISPR-Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment","volume":"121","author":"Ahmadi","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41589-024-01593-6","article-title":"Structures, mechanisms and applications of RNA-centric CRISPR-Cas13","volume":"20","author":"Yang","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-021-01431-6","article-title":"Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Hannafon, B.N., Cai, A., Calloway, C.L., Xu, Y.F., Zhang, R., Fung, K.M., and Ding, W.Q. (2019). miR-23b and miR-27b are oncogenic microRNAs in breast cancer: Evidence from a CRISPR\/Cas9 deletion study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5839-2"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41388-021-02089-6","article-title":"CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer","volume":"41","author":"Yi","year":"2022","journal-title":"Oncogene"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Uddin, F., Rudin, C.M., and Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01387"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41467-023-36452-w","article-title":"A versatile, high-efficiency platform for CRISPR-based gene activation","volume":"14","author":"Heidersbach","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Cai, R., Lv, R., Shi, X., Yang, G., and Jin, J. (2023). CRISPR\/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914865"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymeth.2020.04.006","article-title":"Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects","volume":"187","author":"Rahman","year":"2021","journal-title":"Methods"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"101379","DOI":"10.1016\/j.crmeth.2026.101379","article-title":"Cellular-state control using ribozyme-scaffolded miRNA-sensing and CRISPR-mediated actuation","volume":"6","author":"Kang","year":"2026","journal-title":"Cell Rep. Methods"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Shu, W.-J., Ma, Z., Jia, L., Guo, B., Tian, X., He, C., and Wang, F. (2025). MiR-ON-CRISPR: A microRNA-activated CRISPR\u2013dCas9 system for precise gene therapy in living cells and mouse models of sepsis. Nucleic Acids Res., 53.","DOI":"10.1093\/nar\/gkaf1037"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10142-024-01455-3","article-title":"Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: A comprehensive review and future prospects","volume":"24","author":"Rajanathadurai","year":"2024","journal-title":"Funct. Integr. Genom."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"31739","DOI":"10.1038\/s41598-025-16911-8","article-title":"CRISPR\/dCas9-TET1\u2013mediated epigenetic editing reactivates miR-200c in breast cancer cells","volume":"15","author":"Zahraei","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Yang, Y., Xu, J., Ge, S., and Lai, L. (2021). CRISPR\/Cas: Advances, Limitations, and Applications for Precision Cancer Research. Front. Med., 8.","DOI":"10.3389\/fmed.2021.649896"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Guo, C., Ma, X., Gao, F., and Guo, Y. (2023). Off-target effects in CRISPR\/Cas9 gene editing. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1143157"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-024-55522-1","article-title":"Rational engineering of minimally immunogenic nucleases for gene therapy","volume":"16","author":"Raghavan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Ewaisha, R., and Anderson, K.S. (2023). Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1138596"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2008.09.086","article-title":"Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells","volume":"377","author":"Fujita","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Marciano","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.arcmed.2012.09.007","article-title":"MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1","volume":"43","author":"Li","year":"2012","journal-title":"Arch. Med. Res."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Shin, J., Xie, D., and Zhong, X.P. (2013). MicroRNA-34a enhances T cell activation by targeting diacylglycerol kinase \u03b6. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077983"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11033-025-10581-5","article-title":"Ectopic expression of miR-34a\/-328 sensitizes breast cancer stem cells to gamma rays\/doxorubicin by BCL2\/ABCG2 targeting","volume":"52","author":"Kouhestani","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3892\/or.2015.4529","article-title":"miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1\u03b1","volume":"35","author":"Wu","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1515\/hsz-2016-0104","article-title":"MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer","volume":"397","author":"Zhu","year":"2016","journal-title":"Biol. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"11641","DOI":"10.18632\/oncotarget.14264","article-title":"MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase","volume":"8","author":"Bayraktar","year":"2017","journal-title":"Oncotarget"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/IJN.S207837","article-title":"Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene","volume":"14","author":"Yan","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/15257770.2019.1671595","article-title":"Inhibition of breast cancer cell proliferation with anti-microRNA oligonucleotides flanked by interstrand cross-linked duplexes","volume":"39","author":"Okumura","year":"2020","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"112564","DOI":"10.1016\/j.biopha.2021.112564","article-title":"Dual antisense oligonucleotide targeting miR-21\/miR-155 synergize photodynamic therapy to treat triple-negative breast cancer and inhibit metastasis","volume":"146","author":"Shang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_191","first-page":"1151","article-title":"Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt\/\u03b2-catenin signaling pathway","volume":"23","author":"Gong","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-019-1039-9","article-title":"miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer","volume":"38","author":"Yu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","article-title":"MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer","volume":"13","author":"Bustos","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Soung, Y.H., Ju, J., and Chung, J. (2023). The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1\/2 Mutation Status by Chemically Modified microRNA-489. Cells, 13.","DOI":"10.3390\/cells13010049"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"41309","DOI":"10.1038\/srep41309","article-title":"The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene","volume":"7","author":"Tormo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Noyan, S., Gurdal, H., and Gur Dedeoglu, B. (2019). Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215894"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1111\/jcmm.15396","article-title":"miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT\/mTOR pathway in breast cancer cells","volume":"24","author":"Fu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00253-025-13620-0","article-title":"MiRNA-based drugs: Challenges and delivery strategies","volume":"109","author":"Wang","year":"2025","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/onc.2015.96","article-title":"MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity","volume":"35","author":"Xue","year":"2016","journal-title":"Oncogene"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12551-017-0392-1","article-title":"Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"Biophys. Rev."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Moraes, F.C., Pichon, C., Letourneur, D., and Chaubet, F. (2021). miRNA Delivery by Nanosystems: State of the Art and Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111901"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/2230-973X.167646","article-title":"An overview of viral and nonviral delivery systems for microRNA","volume":"5","author":"Yang","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1089\/nat.2014.0486","article-title":"Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic Proteins","volume":"24","author":"Park","year":"2014","journal-title":"Nucleic Acid. Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2002-07-2314","article-title":"Side effects of retroviral gene transfer into hematopoietic stem cells","volume":"101","author":"Baum","year":"2003","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/jgm.958","article-title":"Lentiviral vector integration sites in human NOD\/SCID repopulating cells","volume":"8","author":"Laufs","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The First Effective In Vivo Gene Delivery Vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-capacity adenoviral vectors: Expanding the scope of gene therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103643"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Watanabe, M., Nishikawaji, Y., Kawakami, H., and Kosai, K.-I. (2021). Adenovirus biology, recombinant adenovirus, and adenovirus usage in gene therapy. Viruses, 13.","DOI":"10.3390\/v13122502"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: Construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Leikas, A.J., Yl\u00e4-Herttuala, S., and Hartikainen, J.E.K. (2023). Adenoviral Gene Therapy Vectors in Clinical Use\u2014Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216519"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1002\/cam4.2935","article-title":"MicroRNA-based recombinant AAV vector assembly improves efficiency of suicide gene transfer in a murine model of lymphoma","volume":"9","author":"Khan","year":"2020","journal-title":"Cancer Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0034-1397352","article-title":"Adeno-associated virus-mediated microRNA delivery and therapeutics","volume":"35","author":"Xie","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41467-025-59088-4","article-title":"Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohorts","volume":"16","author":"Mietzsch","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1039\/D4NR01300J","article-title":"Chemical approaches to probe and engineer AAV vectors","volume":"16","author":"Pham","year":"2024","journal-title":"Nanoscale"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41434-024-00500-x","article-title":"Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy\u2014An update","volume":"32","author":"Joussain","year":"2025","journal-title":"Gene Ther."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1089\/hum.2009.019","article-title":"Immune responses to herpesviral vectors","volume":"20","author":"Ryan","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-14-1140","article-title":"Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance","volume":"74","author":"Park","year":"2014","journal-title":"Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.21037\/tcr-22-824","article-title":"Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: An in vitro and xenograft mouse-model study","volume":"11","author":"Li","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1158\/0008-5472.CAN-13-3710","article-title":"MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development","volume":"74","author":"Deng","year":"2014","journal-title":"Cancer Res."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Long, X., Shi, Y., Ye, P., Guo, J., Zhou, Q., and Tang, Y. (2019). MicroRNA-99a Suppresses Breast Cancer Progression by Targeting FGFR3. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01473"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4149\/neo_2014_082","article-title":"Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122","volume":"61","author":"Yan","year":"2014","journal-title":"Neoplasma"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/gt.2015.52","article-title":"Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors","volume":"22","author":"Trepel","year":"2015","journal-title":"Gene Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/2326-6066.CIR-22-0318","article-title":"A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors","volume":"11","author":"Huang","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Ren, S., Wang, M., Wang, C., Wang, Y., Sun, C., Zeng, Z., Cui, H., and Zhao, X. (2021). Application of Non-Viral Vectors in Drug Delivery and Gene Therapy. Polymers, 13.","DOI":"10.3390\/polym13193307"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1039\/C8TB02946F","article-title":"Non-viral nanocarriers for intracellular delivery of microRNA therapeutics","volume":"7","author":"Bai","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/JME-07-0160","article-title":"RNAs as extracellular signaling molecules","volume":"40","author":"Dinger","year":"2008","journal-title":"J. Mol. Endocrinol."},{"key":"ref_230","unstructured":"Basu, S.C., and Basu, M. (2008). Liposome Methods and Protocols, Springer Science & Business Media."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"26777","DOI":"10.1039\/D0RA03491F","article-title":"A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems","volume":"10","author":"Duan","year":"2020","journal-title":"RSC Adv."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Shah, R., Eldridge, D., Palombo, E., and Harding, I. (2015). Lipid Nanoparticles: Production, Characterization and Stability, Springer.","DOI":"10.1007\/978-3-319-10711-0"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: Structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1039\/D4NR04778H","article-title":"Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery","volume":"17","author":"Yun","year":"2025","journal-title":"Nanoscale"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ncrna.2023.10.002","article-title":"Methods of miRNA delivery and possibilities of their application in neuro-oncology","volume":"8","author":"Gareev","year":"2023","journal-title":"Non-Coding RNA Res."},{"key":"ref_236","first-page":"1677","article-title":"MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression","volume":"44","author":"Xue","year":"2024","journal-title":"J. South. Med. Univ."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1002\/jcb.28574","article-title":"Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition","volume":"120","author":"Zhang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1039\/D4TB01090F","article-title":"Maximising efficacy in HER2-positive breast cancer: Immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy","volume":"13","author":"Chaudhari","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.omtn.2021.01.016","article-title":"NcRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer","volume":"23","author":"Gorur","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s13346-019-00645-y","article-title":"Delivery of therapeutic miRNA using polymer-based formulation","volume":"9","author":"Ban","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1021\/mp300081s","article-title":"Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing","volume":"9","author":"Cheng","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.colsurfb.2018.12.006","article-title":"A novel MUC1 aptamer-modified PLGA-epirubicin-P\u03b2AE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo","volume":"175","author":"Bahreyni","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1021\/nn507465d","article-title":"Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy","volume":"9","author":"Devulapally","year":"2015","journal-title":"ACS Nano"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e2302094","DOI":"10.1002\/adhm.202302094","article-title":"Polymer-Initiating Caveolae-Mediated Endocytosis and GSH-Responsive MiR-34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy","volume":"12","author":"Han","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.molpharmaceut.6b00726","article-title":"PEGylated Cationic Vectors Containing a Protease-Sensitive Peptide as a miRNA Delivery System for Treating Breast Cancer","volume":"14","author":"Zeng","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jconrel.2020.07.029","article-title":"\u201cStar\u201d miR-34a and CXCR4 antagonist based nanoplex for binary cooperative migration treatment against metastatic breast cancer","volume":"326","author":"Yang","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"18435","DOI":"10.1021\/acsomega.2c07866","article-title":"Layered Double Hydroxide-Loaded miR-30a for the Treatment of Breast Cancer In Vitro and In Vivo","volume":"8","author":"Zhang","year":"2023","journal-title":"ACS Omega"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"150","DOI":"10.20517\/evcna.2021.25","article-title":"New insights of engineering plant exosome-like nanovesicles as a nanoplatform for therapeutics and drug delivery","volume":"3","author":"Shinge","year":"2022","journal-title":"Extracell. Vesicles Circ. Nucleic Acids"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12967-025-07657-y","article-title":"Plant-derived exosome-like nanovesicles: Dual-function platforms for anticancer therapy and drug delivery","volume":"24","author":"Zuo","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_251","first-page":"89","article-title":"New therapeutic players on the horizon: Edible plant derived exosomes","volume":"2","author":"Kantarcioglu","year":"2021","journal-title":"Hepatol. Forum"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"e30630","DOI":"10.1016\/j.heliyon.2024.e30630","article-title":"Plant-derived exosome-like nanovesicles: A novel nanotool for disease therapy","volume":"10","author":"Jin","year":"2024","journal-title":"Heliyon"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"106733","DOI":"10.1016\/j.phrs.2023.106733","article-title":"Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment","volume":"190","author":"Yi","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jconrel.2024.01.060","article-title":"Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy","volume":"367","author":"Yan","year":"2024","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Shkryl, Y., Tsydeneshieva, Z., Menchinskaya, E., Rusapetova, T., Grishchenko, O., Mironova, A., Bulgakov, D., Gorpenchenko, T., Kazarin, V., and Tchernoded, G. (2024). Exosome-like Nanoparticles, High in Trans-\u03b4-Viniferin Derivatives, Produced from Grape Cell Cultures: Preparation, Characterization, and Anticancer Properties. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092142"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"103386","DOI":"10.1016\/j.drudis.2022.103386","article-title":"Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies","volume":"27","author":"Amaldoss","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cocis.2014.03.004","article-title":"Inorganic nanoparticles for therapeutic delivery: Trials, tribulations and promise","volume":"19","author":"Tonga","year":"2014","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"ref_258","first-page":"225","article-title":"Engineered gold nanoparticle-based miRNA precision regulation for tumor diagnosis and synergistic therapy","volume":"6","author":"Chen","year":"2025","journal-title":"Smart Mater. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/ac202749p","article-title":"MicroRNA Conjugated Gold Nanoparticles and Cell Transfection","volume":"84","author":"Crew","year":"2012","journal-title":"Anal. Chem."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1038\/s41598-022-08185-1","article-title":"MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells","volume":"12","author":"Chaudhari","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1158\/1535-7163.MCT-18-0702","article-title":"Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis","volume":"18","author":"Ramchandani","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2016.03.008","article-title":"Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy","volume":"228","author":"Ren","year":"2016","journal-title":"J. Control. Release"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:24:26Z","timestamp":1787300666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":262,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162708"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162708","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}